Symposia: Cellular Immunotherapies: Late Phase and Commercially Available Therapies
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, ALL, Lymphomas, Clinical Research, B Cell lymphoma, Plasma Cell Disorders, Diseases, real-world evidence, registries, Lymphoid Malignancies
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, ALL, Lymphomas, Clinical Research, B Cell lymphoma, Plasma Cell Disorders, Diseases, real-world evidence, registries, Lymphoid Malignancies
Monday, December 11, 2023: 4:30 PM-6:00 PM
Room 6CF
(San Diego Convention Center)
Moderators:
Krina K. Patel, MD, MSc, The University of Texas MD Anderson Cancer Center
and
Larry D. Anderson Jr., MD, PhD, UT Southwestern Medical Center
Disclosures:
Patel: AbbVie; Arcellx, AstraZeneca; Bristol Myers Squibb/Celgene Corporation; Caribou Science; Cellectis; Curio Bioscience; Genentech; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; Precision BioSciences: Consultancy; AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb/Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.: Research Funding; Takeda: Consultancy. Anderson: Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Beigene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Cellectar: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Prothena: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees.
This session focuses on clinical trial updates and real world data for Hematologic Malignancies including multiple myeloma, B-cell ALL and B-cell lymphomas.
4:30 PM
4:45 PM
5:00 PM
5:15 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH